Juvenile Idiopathic Arthritis (JIA)

  1. What is Juvenile Idiopathic Arthritis?
  2. The Seven JIA Subtypes
  3. Uveitis: The Silent Eye Threat
  4. Macrophage Activation Syndrome
  5. Diagnosing JIA
  6. Treatment: From NSAIDs to Biologics
  7. Living with JIA: School, Exercise, and Growth
  8. Long-Term Outcomes by Subtype
  9. Key Research Papers
  10. Connections
  11. Featured Videos

What is Juvenile Idiopathic Arthritis?

Juvenile Idiopathic Arthritis (JIA) is the most common chronic inflammatory arthritis in children, affecting approximately 1 in 1,000 children worldwide. It is not a single disease but an umbrella term covering seven distinct subtypes, all sharing the same core requirement: arthritis onset before age 16, lasting more than six weeks, with no other identifiable cause. The "idiopathic" in the name simply means we do not yet know exactly why it starts.

JIA is fundamentally different from adult rheumatoid arthritis (RA). While some subtypes share features with RA — particularly the RF-positive polyarticular form — most JIA subtypes have different genetics, immune mechanisms, and clinical courses. Treating a child with JIA as though they have "early adult RA" misses critical distinctions that affect eye screening, choice of medication, and long-term monitoring.

The disease was first formally described in 1897 by British physician George Frederic Still, who documented a group of children with chronic arthritis accompanied by fever, rash, and enlarged lymph nodes — now recognized as systemic JIA. For most of the 20th century, the condition was called Juvenile Rheumatoid Arthritis (JRA) in the United States and Juvenile Chronic Arthritis (JCA) in Europe. In 1994, the International League of Associations for Rheumatology (ILAR) developed a unified classification system that replaced both older terms, calling the entire group Juvenile Idiopathic Arthritis and defining seven subtypes based on clinical features present in the first six months of disease.

JIA is the leading cause of disability from arthritis in children. Untreated or poorly controlled, it can permanently damage joints, stunt growth, and — through a complication called uveitis — cause irreversible vision loss. Modern biologic therapies have dramatically changed the prognosis for many children, with remission now achievable in a substantial proportion of patients.

Back to Table of Contents

The Seven JIA Subtypes (ILAR Classification)

Understanding which subtype a child has is essential — each carries different risks, requires different monitoring, and may respond better to different treatments. The ILAR classification is based on features present during the first six months of illness.

1. Systemic JIA (sJIA)

Systemic JIA accounts for 10–15% of all JIA cases and is the most biologically distinct subtype. Unlike all other JIA subtypes, sJIA is primarily an autoinflammatory condition — not an autoimmune one. The driving force is innate immune dysregulation, with marked elevation of interleukin-1 beta (IL-1β) and interleukin-18 (IL-18), rather than the T-cell and autoantibody-mediated damage seen in other forms.

The hallmark features of sJIA are:

The life-threatening complication of sJIA is Macrophage Activation Syndrome (MAS) — described in detail in the next section.

2. Oligoarticular JIA

Oligoarticular JIA is the most common subtype, accounting for roughly 50% of all JIA cases. "Oligo" means few — by definition, no more than four joints are affected during the first six months of disease. The knee is the single most commonly involved joint, followed by the ankle and wrist.

About 80% of children with oligoarticular JIA test positive for antinuclear antibodies (ANA). ANA positivity is not a marker of disease severity in joints, but it is strongly associated with the most dangerous complication of this subtype: chronic anterior uveitis. Uveitis in oligoarticular JIA is typically completely asymptomatic — no pain, no redness, no light sensitivity — which means the child cannot report it. Regular slit-lamp eye examinations by an ophthalmologist are mandatory (see the Uveitis section below).

Oligoarticular JIA is further divided into persistent (never exceeds four joints) and extended (spreads to five or more joints after the first six months). Extended oligoarticular disease has a worse prognosis and may require more aggressive treatment.

3. Polyarticular RF-Negative JIA

This subtype involves five or more joints from the start and tests negative for rheumatoid factor (RF). It accounts for about 25% of JIA cases and is a heterogeneous group — these children do not all have the same underlying biology. Treatment typically starts with naproxen for symptom control, progresses to methotrexate as a disease-modifying agent, and may require TNF inhibitors or other biologics if inadequate response.

4. Polyarticular RF-Positive JIA

This is the rarest subtype, affecting only about 5% of children with JIA, but it is the most similar to adult rheumatoid arthritis. Children test positive for rheumatoid factor (RF), and anti-cyclic citrullinated peptide (anti-CCP) antibodies are often positive as well. The disease tends to be aggressive, affecting many joints symmetrically, and most commonly persists into adulthood. RF-positive JIA typically requires early, aggressive DMARD therapy.

5. Enthesitis-Related Arthritis (ERA)

Enthesitis-related arthritis preferentially affects boys and tends to appear in older children and teenagers. "Enthesitis" refers to inflammation at the points where tendons and ligaments attach to bone — the Achilles tendon insertion, the plantar fascia, and the area around the patella are common sites. Large joints of the lower extremities (hips, knees, ankles) are most commonly affected.

About 90% of children with ERA carry the HLA-B27 gene, making it strongly associated with the spondyloarthropathy family of diseases. ERA is considered a pediatric form of spondyloarthritis, and a significant percentage of affected children will eventually develop ankylosing spondylitis (now called axial spondyloarthritis) as adults. Unlike oligoarticular JIA, uveitis in ERA is acute and symptomatic — any sudden-onset red, painful eye in a child with ERA should be treated as an ophthalmic emergency.

6. Psoriatic JIA

Psoriatic JIA is diagnosed when a child has arthritis plus either a confirmed psoriasis diagnosis, or any two of the following: dactylitis (the "sausage digit" — diffuse swelling of an entire finger or toe), nail pitting, or a first-degree relative with psoriasis. The joint distribution is often asymmetric and can involve small joints of the hands and feet as well as larger joints. Uveitis risk is present, and monitoring is required.

7. Undifferentiated JIA

This category captures children whose arthritis does not fulfill criteria for any single subtype, or who meet criteria for more than one subtype simultaneously. It is a holding category rather than a distinct biological entity, and management is guided by the dominant clinical features.

Back to Table of Contents

Uveitis: The Silent Eye Threat

Of all the complications of JIA, chronic anterior uveitis is the one most likely to cause permanent harm if not caught early — and the one most likely to be missed because it causes no symptoms until significant damage has occurred.

Uveitis is inflammation of the uvea, the middle layer of the eye containing the iris, ciliary body, and choroid. In children with oligoarticular JIA, the form is chronic anterior uveitis — meaning it affects the front of the eye, tends to be long-lasting, and crucially, is typically completely asymptomatic. The affected child has no eye pain, no redness, no photophobia, and no blurred vision in early stages. The only way to detect it is through a slit-lamp examination performed by an ophthalmologist.

If uveitis goes undetected and untreated, the inflamed iris can form adhesions (synechiae) to the lens, leading to glaucoma, cataracts, band keratopathy (calcium deposits across the cornea), and ultimately permanent vision loss. JIA-associated uveitis is one of the leading causes of preventable blindness in children in developed countries.

Who is at highest risk? The combination of ANA positivity, age under 7 at diagnosis, and oligoarticular disease creates the highest-risk profile. These children require ophthalmology screening every 3 months. Risk factors that lower the required frequency include older age at diagnosis, ANA negativity, and longer disease duration without uveitis.

Screening schedule (approximate — follow rheumatologist guidance):

Treatment of uveitis: Topical corticosteroid eye drops are the first-line acute treatment. Methotrexate and mycophenolate mofetil are used as steroid-sparing agents. Adalimumab (a TNF inhibitor) has become the biologic of choice for JIA-associated uveitis — a landmark 2017 randomized trial (Ramanan et al., NEJM 2017) demonstrated that adalimumab plus methotrexate significantly reduced treatment failure compared to methotrexate alone in children with refractory uveitis.

A critical point for families: the activity of uveitis does not track with joint disease activity. A child whose arthritis appears well-controlled can still be developing active uveitis. Never skip eye appointments because the joints seem fine.

Back to Table of Contents

Macrophage Activation Syndrome (MAS)

Macrophage Activation Syndrome is a rare but potentially life-threatening complication of JIA, occurring most commonly — and most severely — in children with systemic JIA. It is a form of secondary hemophagocytic lymphohistiocytosis (HLH), in which immune cells called macrophages become uncontrollably activated and begin engulfing blood cells throughout the body.

What triggers MAS? Known triggers include viral infections (Epstein-Barr virus and cytomegalovirus are particularly associated), NSAID use, and initiation or dose changes of certain biologic therapies, particularly IL-6 inhibitors. However, MAS can develop without any identifiable trigger, and it can emerge even in children whose systemic JIA appeared to be well-controlled.

Warning signs: MAS presents as a clinical deterioration that can be mistaken for a JIA flare or infection. Key features include:

Treatment: MAS requires urgent, aggressive treatment. High-dose corticosteroids (often intravenous methylprednisolone) are the first-line intervention. IL-1 inhibitors — particularly anakinra (given subcutaneously or intravenously, rapidly adjustable dose) and canakinumab — have transformed outcomes in sJIA-MAS. Cyclosporine is added in severe or refractory cases. Etoposide is reserved for the most severe presentations. Early recognition and aggressive treatment are critical to survival.

Families of children with systemic JIA should know the warning signs of MAS and have a clear plan from their rheumatologist about when to seek emergency care. A sJIA child who develops persistent fever that no longer follows the quotidian pattern, combined with unusual fatigue or bruising, should be evaluated urgently.

Back to Table of Contents

Diagnosing JIA

JIA is a clinical diagnosis — there is no single blood test or imaging finding that confirms it. Diagnosis requires excluding other causes of childhood arthritis and meeting the ILAR criteria for one of the seven subtypes. This process can take time, and the average delay from first symptom to formal diagnosis is three to six months.

Who should be evaluated? Any child with joint swelling, morning stiffness lasting more than 30 minutes, or a limp that persists for more than six weeks should be referred to a pediatric rheumatologist. Parents often notice that their child is stiff and reluctant to walk in the mornings but "loosens up" after moving around — this pattern is highly suggestive of inflammatory arthritis.

Laboratory evaluation:

Imaging: Plain X-rays are often normal early in JIA but are useful for detecting joint damage in established disease. Musculoskeletal ultrasound can detect synovial thickening and effusion not apparent on physical exam. MRI provides the most detailed view of soft tissue inflammation and early erosive disease, and is particularly useful for evaluating the hip, sacroiliac joints (ERA), and temporomandibular joint (jaw involvement).

The differential diagnosis: Several conditions can mimic JIA and must be considered:

Back to Table of Contents

Treatment: From NSAIDs to Biologics

JIA treatment has been transformed over the past two decades by the introduction of biologic therapies. The goal is not simply to control symptoms but to achieve clinical remission — no active arthritis, no uveitis activity, no systemic features — ideally allowing eventual medication tapering. Treatment follows a stepwise approach based on subtype, severity, and treatment response.

Step 1: NSAIDs

Naproxen is the most commonly used NSAID in pediatric rheumatology. It reduces pain and stiffness and can control mild oligoarticular disease in some children. Naproxen does not prevent joint damage and does not modify the underlying immune process — it is symptom management. A rare side effect specific to children is naproxen-induced pseudoporphyria, a sun-sensitive skin blistering reaction. Ibuprofen and indomethacin are alternatives.

Step 2: Intra-articular Corticosteroids

For oligoarticular JIA with one or two large joints, injection of triamcinolone hexacetonide directly into the joint can provide months of remission. This is often a first-line approach alongside NSAIDs for oligoarticular disease, avoiding systemic medications. Injections may be repeated, though repeated injections carry a small risk of local skin changes.

Step 3: Methotrexate (MTX)

Methotrexate is the cornerstone disease-modifying therapy for JIA. It is given weekly — typically 10–15 mg/m² body surface area, administered subcutaneously (under the skin) for better absorption and fewer gastrointestinal side effects than oral dosing. Folic acid (1 mg daily or 5 mg once weekly) is given alongside to reduce side effects including nausea, mouth sores, and liver enzyme elevation. MTX takes 2–3 months to show full effect. Regular monitoring of blood counts and liver function is required. MTX is teratogenic and requires reliable contraception in adolescents.

Step 4: Biologic Therapies

When methotrexate is insufficient — or when disease is severe from the start — biologic medications targeting specific inflammatory pathways are used. The choice of biologic depends on the JIA subtype:

TNF inhibitors (etanercept, adalimumab): The most widely used biologics in JIA. Etanercept was the first biologic approved for JIA and has an excellent safety record. Adalimumab is preferred when uveitis is present or at high risk, as clinical trial data (Ramanan 2017, NEJM) demonstrated superiority over placebo for JIA uveitis — etanercept has shown less effectiveness for eye disease. Both are given by subcutaneous injection.

IL-6 receptor inhibitor (tocilizumab): Approved for polyarticular JIA (all subtypes) and systemic JIA. Particularly useful when methotrexate has been insufficient. Given intravenously or subcutaneously.

IL-1 inhibitors (anakinra, canakinumab): The treatment of choice for systemic JIA. Anakinra acts within hours and can be rapidly dose-adjusted — invaluable in MAS. Canakinumab (anti-IL-1β monoclonal antibody) is given by subcutaneous injection every 4 weeks and has shown dramatic efficacy in sJIA in two large randomized trials (Ruperto 2012, NEJM). These agents do not generally work as well for non-systemic JIA subtypes.

T-cell costimulation inhibitor (abatacept): Blocks the second signal needed to activate T cells. Approved for polyarticular JIA inadequately responding to methotrexate or TNF inhibitors. A landmark placebo-controlled withdrawal trial (Ruperto 2008, Lancet) demonstrated maintained efficacy. Given intravenously or subcutaneously.

IL-17A inhibitor (secukinumab): The most targeted option for enthesitis-related arthritis and juvenile psoriatic arthritis. The JUNIPSA trial (Brunner 2023, Ann Rheum Dis) demonstrated significant improvement in disease activity in children with ERA and juvenile psoriatic JIA. Particularly useful when axial involvement (sacroiliitis) is present.

Uveitis-specific treatment pathway: Topical corticosteroid drops → methotrexate (systemic) → adalimumab. Adalimumab is currently the only biologic with strong randomized trial evidence specifically for JIA uveitis.

Systemic Corticosteroids

Oral or intravenous corticosteroids (prednisone, methylprednisolone) are powerful anti-inflammatory agents used in acute flares, during MAS, and as bridging therapy while awaiting DMARD or biologic effect. Long-term systemic corticosteroids are avoided as much as possible in children because of serious side effects including growth suppression, bone loss, weight gain, and adrenal suppression.

Back to Table of Contents

Living with JIA: School, Exercise, and Growth

JIA is a condition that touches every aspect of a child's life — not just their joints. Managing it well means addressing school, physical activity, emotional wellbeing, and the practicalities of growing up with a chronic illness.

School accommodations: Children with JIA often need formal accommodations at school. Morning stiffness can make early school start times particularly difficult. Practical accommodations include: permission to arrive late on high-stiffness days, extra time on tests, access to an elevator, permission to carry a second set of books, a seat near the front, and unrestricted access to water (some medications increase thirst). A 504 Plan or Individualized Education Program (IEP) can formalize these supports. Pediatric rheumatology teams often have social workers who can help with school letters and advocacy.

Exercise — essential, not optional: Parents often worry that activity will damage their child's joints. The opposite is true: regular physical activity is one of the most important components of JIA management. Exercise maintains joint range of motion, preserves muscle strength around inflamed joints (reducing joint stress), improves cardiovascular fitness, and supports mental health. Swimming and cycling are excellent low-impact options, but most children with controlled JIA can participate in the activities they enjoy. Physical and occupational therapists skilled in pediatric rheumatology can design appropriate programs and teach joint protection techniques.

Growth monitoring: JIA and its treatments can affect growth. Active systemic inflammation suppresses growth hormone signaling. Corticosteroids cause the most significant growth suppression with long-term use. Methotrexate generally does not impair growth at standard doses. Biologic therapies, by controlling inflammation, tend to allow catch-up growth. Height and weight should be plotted at every rheumatology visit.

Vaccinations: Children with JIA on immunosuppressive therapy (methotrexate, biologics) should not receive live vaccines (MMR, varicella, live-attenuated influenza). Ideally, a child's vaccination schedule should be completed before starting immunosuppressive therapy. Annual killed influenza vaccine is recommended. Meningococcal, pneumococcal, and HPV vaccines are appropriate and important for children on immunosuppression.

Transition to adult care: Around age 18, teenagers with JIA transfer from pediatric rheumatology to adult rheumatology. This transition is a vulnerable time — disease flares are common when care changes. Proactive transition planning should begin at age 14–16, with the teenager learning to manage their own condition, know their medications and doses, and advocate for themselves in medical appointments.

Mental health: Chronic pain, unpredictable flares, medication side effects, and social isolation from missing school and activities place children with JIA at higher risk for anxiety and depression. These are legitimate medical concerns, not signs of weakness. Psychological support — counseling, peer support groups, disease-specific summer camps — should be an integrated part of comprehensive care.

Back to Table of Contents

Long-Term Outcomes by Subtype

The long-term trajectory of JIA varies substantially by subtype. Modern biologic therapies have dramatically improved outcomes across all categories compared to earlier decades, but JIA remains a condition where careful monitoring throughout childhood — and into adulthood for many — is necessary.

Oligoarticular JIA: The best overall prognosis of all JIA subtypes. Persistent oligoarticular disease (never more than four joints) has the highest likelihood of medication-free remission. The major long-term risk is uveitis-related vision loss if eye screening is neglected. Extended oligoarticular disease (spreading to five or more joints) has a more variable course.

Polyarticular RF-Negative JIA: Heterogeneous outcomes. Some children achieve remission; others have persistent disease. The absence of RF suggests a different underlying biology from adult RA, and outcomes are generally better than RF-positive disease.

Polyarticular RF-Positive JIA: The most challenging long-term outlook. Most children with RF-positive JIA will have persistent disease into adulthood, indistinguishable from adult RA. Early, aggressive DMARD therapy is justified to prevent erosive joint damage.

Systemic JIA: Approximately 50% of children with sJIA achieve remission and can eventually discontinue medications. The remaining 50% have a chronic course with persistent arthritis and ongoing systemic inflammation. MAS is the most dangerous acute complication and can be fatal even with optimal treatment. IL-1 inhibitors have substantially reduced MAS-related mortality.

Enthesitis-Related Arthritis: A significant proportion of children with ERA will develop axial spondyloarthritis or ankylosing spondylitis as adults, particularly those who are HLA-B27 positive and develop sacroiliac joint inflammation. Early IL-17 inhibitor or TNF inhibitor therapy may alter this trajectory.

Psoriatic JIA: Persistent disease is common. Psoriasis skin disease tends to be lifelong. A subset develop a destructive arthritis mutilans pattern affecting small joints of the hands.

The impact of biologics: Across all subtypes, children who achieve sustained remission on biologic therapy appear to have substantially better structural outcomes (less joint damage on imaging) than pre-biologic era cohorts. The field is moving toward treat-to-target strategies — aiming for defined clinical remission criteria (such as those proposed by Wallace et al., 2004) — and tapering therapy once remission is achieved rather than maintaining indefinite medication.

Back to Table of Contents

Key Research Papers

  1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392. PMID: 14760812 — The foundational ILAR classification paper defining the seven JIA subtypes used worldwide.
  2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778. PMID: 17336654 — Comprehensive landmark review covering pathogenesis, classification, clinical features, and treatment.
  3. Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290–2294. PMID: 15517647 — Defines clinical remission criteria used in treat-to-target strategies.
  4. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–391. PMID: 18632147 — Pivotal trial establishing abatacept efficacy for polyarticular JIA.
  5. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–820. PMID: 18715278 — Randomized trial demonstrating adalimumab efficacy in polyarticular JIA with and without methotrexate.
  6. Brunner HI, Foeldvari I, Alexeeva E, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial (JUNIPSA). Ann Rheum Dis. 2023;82(6):798–808. PMID: 36898730 — First phase 3 trial demonstrating secukinumab (IL-17A inhibitor) efficacy in ERA and juvenile psoriatic arthritis.
  7. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646. PMID: 28445673 — Landmark randomized trial establishing adalimumab as the standard of care for refractory JIA-associated uveitis.
  8. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–2406. PMID: 23252526 — Pivotal phase 3 trials demonstrating canakinumab (anti-IL-1β) efficacy in systemic JIA.
  9. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2011;70(5):747–754. PMID: 21068096 — Randomized trial supporting anakinra for systemic JIA; particularly relevant given anakinra's rapid adjustability in MAS.
  10. Shenoi S, Horneff G, Melo-Gomes JA, et al. Tocilizumab in systemic juvenile idiopathic arthritis: data from the German biologics JIA registry and literature update. Rheumatology (Oxford). 2021;60(4):1627–1638. PMID: 33021626 — Registry data and literature synthesis on tocilizumab (IL-6R inhibitor) in systemic JIA.
  11. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(4):465–482. PMID: 21452260 — ACR treatment guidelines providing stepwise management recommendations by JIA subtype and disease activity.
  12. Minden K, Niewerth M. Clinical perspectives of juvenile idiopathic arthritis — classification and current treatment. Pediatr Drugs. 2021;23(2):105–114. PMID: 33704687 — Accessible review of JIA classification and the current biologic treatment landscape.

Back to Table of Contents

Connections

Featured videos are curated and added via the site's video pipeline. This section will contain 16 educational videos on Juvenile Idiopathic Arthritis from trusted pediatric rheumatology sources.